Abstract
Pegfilgrastim is a granulocyte colony‐stimulating factor (G‐CSF) with a long half‐life and sustained duration of action. Pegfilgrastim is created with pegylation technology, whereby a 20‐kD polyethylene glycol moiety is conjugated to filgrastim (recombinant human G‐CSF), resulting in a larger molecule. Consequently, its renal clearance by glomerular filtration is minimized, making neutrophil‐mediated clearance the predominant route of elimination. Preclinical animal data have shown that the clearance of pegfilgrastim depends on dosage and absolute neutrophil count, with pegfilgrastim having a longer circulating half‐life and more sustained duration of action than filgrastim. The biologic effect of pegfilgrastim is prolonged in a neutropenic setting because few mature neutrophils are available to mediate its elimination. Clinical trials have suggested that neutrophil‐mediated clearance of pegfilgrastim may be self‐regulating and may therefore be specific to each patient's hematopoietic recovery.

This publication has 13 references indexed in Scilit: